Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention
Journal of Cardiothoracic Surgery · 2024
DOI: 10.1186/s13019-024-03052-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiothoracic Surgery, 2024. Verfasst von Heng Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, 215101, Jiangsu Province, China. Hauptthemen laut MEDLINE: Atorvastatin, Percutaneous Coronary Intervention, Contrast Media, Kidney Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: At present, the clinical methods for preventing and treating contrast-induced nephropathy (CIN) are limited, and statins can play a better role during this process. So, we aimed to assess the atorvastatin on renal function in nephropathy patients after percutaneous coronary intervention (PCI). METHODS: In this work, 100 elderly patients with coronary heart disease (CHD) were selected into an experimental group (Exp group, 50 cases, 40 mg/d po atorvastatin) and a control group (Ctrl group, 50 cases, 10 mg/d po atorvastatin). The renal function indicators, blood routine indicators, and the incidence of adverse reactions (ARs) were compared between patients in Exp and Ctrl groups. RESULTS: After surgery, the levels of serum creatinine (SCr), blood urea nitrogen (BUN), cystatin C (CysC), high-sensitivity C-reactive protein (hs-CRP), and interleukin (IL6) in patients in the Exp group were much lower, and the levels of estimated glomerular filtration rate (eGFR) and superoxide dismutase (SOD) were higher (all P 0.05). Compared with conventional doses of atorvastatin, high-dose atorvastatin can effectively prevent renal function damage in patients with CIN, decrease the inflammation and oxidative stress in patients, and will not increase the risk of ARs during hospitalization. CONCLUSION: Taken together, high-dose atorvastatin can be applied in treating patients with CHD after PCI due to its excellent efficacy and high safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, 215101, Jiangsu Province, China.
- Department of Cardiology, Suzhou Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou, 215101, Jiangsu Province, China. cenbidong404@163.com.
Zitieren
APA
Li, H., Wang, H., Ren, S., & Zhou, R. (2024). Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention. Journal of Cardiothoracic Surgery. https://doi.org/10.1186/s13019-024-03052-8
Vancouver
Li H, Wang H, Ren S, Zhou R. Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention. Journal of Cardiothoracic Surgery. 2024. doi:10.1186/s13019-024-03052-8
BibTeX
@article{Li2024,
author = {Li, Heng and Wang, Hongen and Ren, Siqi and Zhou, Ruihong},
title = {Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention},
journal = {Journal of Cardiothoracic Surgery},
year = {2024},
doi = {10.1186/s13019-024-03052-8}
}
EUVIMED